Evaxion A/S (EVAX) Projected to Announce Earnings on Thursday

Evaxion A/S (NASDAQ:EVAX – Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect Evaxion A/S to announce earnings of ($0.01) per share and revenue of $0.30 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 8:30 AM ET.

Evaxion A/S Trading Up 0.4%

Evaxion A/S stock opened at $2.78 on Wednesday. The business has a 50 day moving average price of $3.11 and a two-hundred day moving average price of $3.42. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. The stock has a market cap of $25.08 million, a price-to-earnings ratio of -2.30 and a beta of 0.60. Evaxion A/S has a 12 month low of $2.65 and a 12 month high of $6.92.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 6th. Wall Street Zen raised Evaxion A/S to a “hold” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.25.

Read Our Latest Stock Report on EVAX

About Evaxion A/S

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

Read More

Earnings History for Evaxion A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.